Crinetics Pharmaceuticals Future Growth

Future criteria checks 2/6

Crinetics Pharmaceuticals is forecast to grow earnings and revenue by 8.7% and 68.1% per annum respectively. EPS is expected to grow by 12.5% per annum. Return on equity is forecast to be -37.2% in 3 years.

Key information

8.7%

Earnings growth rate

12.5%

EPS growth rate

Biotechs earnings growth	27.7%
Revenue growth rate	68.1%
Future return on equity	-37.2%
Analyst coverage	Good
Last updated	16 Dec 2024

Recent future growth updates

Recent updates

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Aug 12

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

Earnings and Revenue Growth Forecasts

NasdaqGS:CRNX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	48	-448	-451	N/A	9
12/31/2025	6	-365	-359	-312	12
12/31/2024	2	-296	-260	-225	12
9/30/2024	1	-278	-204	-200	N/A
6/30/2024	1	-259	-185	-178	N/A
3/31/2024	2	-235	-184	-178	N/A
12/31/2023	4	-215	-171	-166	N/A
9/30/2023	5	-199	-167	-163	N/A
6/30/2023	5	-184	-161	-160	N/A
3/31/2023	4	-175	-144	-142	N/A
12/31/2022	5	-164	-117	-115	N/A
9/30/2022	5	-150	-104	-103	N/A
6/30/2022	5	-136	-91	-90	N/A
3/31/2022	4	-119	-82	-82	N/A
12/31/2021	1	-108	-89	-89	N/A
9/30/2021	N/A	-98	-82	-82	N/A
6/30/2021	N/A	-89	-74	-74	N/A
3/31/2021	N/A	-79	-70	-70	N/A
12/31/2020	0	-74	-62	-62	N/A
9/30/2020	0	-67	-60	-60	N/A
6/30/2020	1	-63	-55	-55	N/A
3/31/2020	1	-59	-52	-52	N/A
12/31/2019	1	-50	-47	-46	N/A
9/30/2019	2	-44	-40	-39	N/A
6/30/2019	2	-38	-32	-31	N/A
3/31/2019	2	-31	-24	-23	N/A
12/31/2018	2	-27	-21	-19	N/A
9/30/2018	2	-21	-17	-16	N/A
6/30/2018	2	-16	N/A	-13	N/A
3/31/2018	2	-12	N/A	-11	N/A
12/31/2017	2	-9	N/A	-9	N/A
12/31/2016	1	-6	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRNX's revenue (68.1% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: CRNX's revenue (68.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CRNX is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/29 16:58
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Crinetics Pharmaceuticals, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Joshua Schimmer	Cantor Fitzgerald & Co.
Charles Duncan	Cantor Fitzgerald & Co.

Crinetics Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 20%

Price target increased by 7.8% to US$66.43

Price target increased by 8.2% to US$61.50

Price target increased by 10% to US$59.79

Price target increased by 7.8% to US$57.23

Price target increased by 9.1% to US$54.46

Recent updates

Crinetics Pharmaceuticals, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer

Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Founder notifies of intention to sell stock

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Crinetics Pharmaceuticals, Inc. Announces Marc Wilson Will Be Transitioning from His Role as Chief Financial Officer

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Chief Operating Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from Russell 2500 Value Index

Chief Commercial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Presents New Data At ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Price target increased by 7.8% to US$66.43

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics Pharmaceuticals, Inc. Appoints Robert M. Cuddihy as Senior Vice President of Medical Affairs

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

Price target increased by 8.2% to US$61.50

Full year 2023 earnings released: US$3.69 loss per share (vs US$3.15 loss in FY 2022)

Founder notifies of intention to sell stock

Price target increased by 10% to US$59.79

Crinetics Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

Chief Development Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.8% to US$57.23

Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly

Price target increased by 9.1% to US$54.46

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Consensus revenue estimates decrease by 88%, EPS upgraded

Consensus revenue estimates decrease by 89%, EPS upgraded

Chief Medical Officer notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors

Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly

Price target increased by 8.2% to US$46.78

Consensus revenue estimates fall by 18%

Price target decreased by 7.4% to US$43.63

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$1.0m worth of stock

Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023

Founder notifies of intention to sell stock

Consensus revenue estimates increase by 154%

Chief Development Officer notifies of intention to sell stock

Chief Development Officer recently sold US$133k worth of stock

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 12%